Free Trial
NASDAQ:CYTK

Cytokinetics (CYTK) Stock Price, News & Analysis

Cytokinetics logo
$33.90 -0.46 (-1.34%)
Closing price 07/3/2025 02:25 PM Eastern
Extended Trading
$34.52 +0.62 (+1.81%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cytokinetics Stock (NASDAQ:CYTK)

Key Stats

Today's Range
$33.85
$34.66
50-Day Range
$29.84
$42.92
52-Week Range
$29.31
$61.38
Volume
1.30 million shs
Average Volume
1.52 million shs
Market Capitalization
$4.05 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$70.92
Consensus Rating
Moderate Buy

Company Overview

Cytokinetics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
79th Percentile Overall Score

CYTK MarketRank™: 

Cytokinetics scored higher than 79% of companies evaluated by MarketBeat, and ranked 218th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 10 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cytokinetics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Cytokinetics' stock forecast and price target.
  • Earnings Growth

    Earnings for Cytokinetics are expected to decrease in the coming year, from ($5.24) to ($5.25) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cytokinetics is -6.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cytokinetics is -6.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Cytokinetics' valuation and earnings.
  • Percentage of Shares Shorted

    12.00% of the float of Cytokinetics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cytokinetics has a short interest ratio ("days to cover") of 6.8.
  • Change versus previous month

    Short interest in Cytokinetics has recently decreased by 3.38%, indicating that investor sentiment is improving.
  • Dividend Yield

    Cytokinetics does not currently pay a dividend.

  • Dividend Growth

    Cytokinetics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.00% of the float of Cytokinetics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cytokinetics has a short interest ratio ("days to cover") of 6.8.
  • Change versus previous month

    Short interest in Cytokinetics has recently decreased by 3.38%, indicating that investor sentiment is improving.
  • Search Interest

    Only 3 people have searched for CYTK on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Cytokinetics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,369,927.00 in company stock.

  • Percentage Held by Insiders

    Only 2.70% of the stock of Cytokinetics is held by insiders.

  • Read more about Cytokinetics' insider trading history.
Receive CYTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.

CYTK Stock News Headlines

This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
Cytokinetics Calls for Donations
See More Headlines

CYTK Stock Analysis - Frequently Asked Questions

Cytokinetics' stock was trading at $47.04 at the start of the year. Since then, CYTK shares have decreased by 27.9% and is now trading at $33.90.

Cytokinetics, Incorporated (NASDAQ:CYTK) issued its quarterly earnings data on Tuesday, May, 6th. The biopharmaceutical company reported ($1.36) EPS for the quarter, beating analysts' consensus estimates of ($1.41) by $0.05. The company's revenue for the quarter was up 89.1% compared to the same quarter last year.
Read the conference call transcript
.

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cytokinetics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Advanced Micro Devices (AMD), Adobe (ADBE) and GE Aerospace (GE).

Company Calendar

Last Earnings
5/06/2025
Today
7/05/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CYTK
Employees
250
Year Founded
1997

Price Target and Rating

Average Stock Price Target
$70.92
High Stock Price Target
$120.00
Low Stock Price Target
$41.00
Potential Upside/Downside
+109.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.93
Research Coverage
15 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$589.53 million
Net Margins
-3,201.47%
Pretax Margin
-3,201.47%

Debt

Sales & Book Value

Annual Sales
$18.47 million
Price / Cash Flow
N/A
Book Value
($1.15) per share
Price / Book
-29.48

Miscellaneous

Free Float
116,202,000
Market Cap
$4.05 billion
Optionable
Optionable
Beta
0.59

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:CYTK) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners